38 results
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
dividend yield and expected volatility of our stock in determining the fair value of the warrants. The risk-free interest rate is based on U.S. Department
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
14 Nov 23
Interim condensed consolidated financial statements of
12:00am
dividend yield and expected volatility of our stock in determining the fair value of the warrants. The risk-free interest rate is based on U.S. Department
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
8 Nov 23
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
10:29am
, the Company announced that it had received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq … the Listing Qualifications Department of the Nasdaq, which notified the Company of the delisting of its securities from the Nasdaq Capital Market
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
8 Nov 23
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
10:29am
the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”), which notified the Company of the delisting of its securities from … and registration on Nasdaq.
As previously announced, on October 25, 2022, the Nasdaq Listing Qualifications Department notified the Company
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
28 Aug 23
Current report (foreign)
4:49pm
4H1, Attention: Proxy Department; by facsimile to 1-416-595-9593; or online with your 12-digit control number at www.voteproxyonline.com, by no later … Street West, Suite 301, Toronto, Ontario, Canada, M5H 4H1, Attention: Proxy Department and must be labeled “Legal Proxy” and received no later than
6-K
EX-99.1
eomtl u6le
8 Aug 23
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
9:36am
6-K
EX-99.1
v3haqa3cqx f0
28 Jul 23
Interim condensed consolidated financial statements of
8:31am
6-K
EX-99.1
apjqesbe21qpd4nen
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
EX-99.1
dx0 ayfgbcweqvet45gs
22 Aug 22
Current report (foreign)
11:39am
6-K
EX-99.1
6kd 0qyg6aj1
11 Aug 22
Medicenna Announces Closing of Public Offering of Units
4:36pm
SUPPL
i8z61wdb7 75cbwlg
10 Aug 22
Supplemental materials (foreign)
3:10pm
6-K
EX-99.1
ri0575fv3bleuphdmwav
9 Aug 22
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units
9:22am
SUPPL
8s3ax3y
8 Aug 22
Supplemental materials (foreign)
8:40pm
20-F
EX-1.3
3yrict26et
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-4.7
22y6myy ynz48
22 Jun 22
Annual report (foreign)
5:04pm
20-F
0j016qdwh6 xzq
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-4.3
zujwm3q6 xy
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-4.6
e9mh bplb
22 Jun 22
Annual report (foreign)
5:04pm